Colorectal Cancer Clinical Trial
Official title:
Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the RP2D of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer. The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158.
Status | Recruiting |
Enrollment | 360 |
Est. completion date | June 2025 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed solid tumors with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent. - Expansion cohorts: patients with locally advanced unresectable or metastatic disease for the following indications: - COMBINATION FIRST-LINE HNSCC: patients eligible to receive pembrolizumab as first-line monotherapy with tumors expressing programmed cell death protein ligand 1 (PD-L1), combined positive score (CPS) =1, as determined by a Food and Drug Administration (FDA) approved test in the US, or by an approved equivalent test in other countries; patients should not have previous systemic therapy administered in the recurrent or metastatic setting, although previous systemic therapy as part of multimodal treatment for locally advanced disease is allowed if ended =6 months prior to signing the ICF. The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Previous treatments with anti PD-(L)1 or anti-EGFR therapies are not allowed. - SINGLE AGENT SECOND-/THIRD-LINE HNSCC PATIENTS: patients who have progressed on or after, or are intolerant to, anti-PD-(L)1 therapy as monotherapy or in combination with other agents, and have progressed to a platinum-based chemotherapy less than 6 months from the last platinum dose, with no previous exposure to EGFR inhibitors. Patients with no more than 2 prior lines of treatment in recurrent or metastatic disease not amenable to standard therapy with curative intent. - Human papilloma virus (HPV) status determined by p16 immunohistochemistry (IHC) or molecular HPV test for all oropharyngeal tumors should be reported when available. - The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. - GEA with histologically confirmed EGFR amplification (fluorescence in situ hybridization [FISH] score EGFR/CEP7 ratio =2.0, or next generation sequencing [NGS] EGFR copy =8, or cfDNA =2.5, or EGFR IHC H-score =200) - Esophageal carcinoma - Pancreatic adenocarcinoma - Patients with other indications must have been previously treated with at least 2 lines of the standard approved therapy (when applicable) in the locally advanced/unresectable or metastatic setting. Patients with malignant salivary gland tumors and squamous esophageal cancer may be enrolled after progression on 1 line of systemic standard treatment. - A baseline fresh tumor sample (FFPE) from a metastatic or primary site. - Amenable for biopsy. - Measurable disease as defined by RECIST version 1.1 by radiologic methods. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Life expectancy = 12 weeks, as per investigator. - Left ventricular ejection fraction (LVEF) = 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA). - Adequate organ function Exclusion Criteria: - Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry. - Known leptomeningeal involvement. - Participation in another clinical trial or treatment with any investigational drug within 4 weeks prior to study entry. - Any systemic anticancer therapy within 4 weeks or 5 half-lives whichever is longer of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity ( e.g. mitomycin C,nitrosoureas), or anticancer immunotherapies, a washout period of 6 weeks is required. - Requirement for immunosuppressive medication (e.g. methotrexate, cyclophosphamide) - Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to =25% of bone marrow are not eligible, irrespective of when it was received. - Persistent grade >1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy = grade 2 NCI-CTCAE v4.03 is allowed. - History of hypersensitivity reaction or any toxicity attributed to human proteins or any of the excipients that warranted permanent cessation of these agents. - Uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg) with appropriate treatment or unstable angina. - History of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia). - History of myocardial infarction within 6 months of study entry. - History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease for at least 3 years. - Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy. - Patients with a history of interstitial lung disease (e.g.: pneumonitis or pulmonary fibrosis) or evidence of ILD on baseline chest CT scan. - Current serious illness or medical conditions including, but not limited to uncontrolled active infection,clinically significant pulmonary, metabolic or psychiatric disorders. - Patients with the following infectious diseases: - Active hepatitis B infection (HBsAg positive) without receiving antiviral treatment. Note: Patients with active hepatitis B (HBsAg positive) must receive antiviral treatment with lamivudine, tenofovir, entecavir, or other antiviral agents, starting at least =7 days before the initiation of the study treatment. Patients with antecedents of hepatitis B (anti-HBc positive, HBsAg and HBV-DNA negative) are eligible. - Positive test for hepatitis C ribonucleic acid (HCV RNA). Note: Patients in whom HCV infection resolved spontaneously (positive HCV antibodies without detectable HCV-RNA) or who achieved a sustained response after antiviral treatment and show absence of detectable HCV RNA =6 months (with the use of IFN-free regimens) or = 12 months (with t the use of IFN-based regimens) after cessation of antiviral treatment are eligible. - Patients with current cirrhotic status of Child-Pugh class B or C; known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC. - Pregnant or lactating women; patients of childbearing potential must use highly effective contraception methods prior to study entry, for the duration of study participation, and for 6 months after the last dose of MCLA-158. |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques universitaires Saint-Luc | Brussels | |
Belgium | Institut Jules Bordet | Brussels | |
Belgium | UZ Gent | Gent | |
Belgium | Chu Ucl Namur Site De Sainte-Elisabeth | Namur | |
France | Hopital Saint Andre, CHU Bordeaux | Bordeaux | |
France | Centre Leon Berard | Lyon | |
France | Hopital La Timone | Marseille | |
France | Institut Régional du Cancer de Montpellier | Montpellier | |
France | Centre Antoine Lacassagne | Nice | |
France | Institut Curie | Paris | |
France | Institut Gustave Roussy | Paris | |
France | Centre Henri Becquerel | Rouen | |
Netherlands | NKI - Antoni van Leeuwenhoek | Amsterdam | |
Netherlands | UMC Radboud | Nijmegen | |
Netherlands | UMC Utrecht | Utrecht | |
Spain | Vall d'Hebron | Barcelona | |
Spain | Hospital 12 de Octubre | Madrid | |
Spain | Clinica Universidad de Navarra | Pamplona | |
Spain | Complejo Hospitalario de Navarra | Pamplona | |
Spain | Instituto Valenciano de Oncologia | Valencia | |
United Kingdom | Cambridge University Hospitals NHS Foundation Trust | Cambridge | |
United Kingdom | Sarah Cannon Research Institute | London | |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Texas Oncology | Dallas | Texas |
United States | Florida Cancer Specialists | Fort Myers | Florida |
United States | Oncology Consultants | Houston | Texas |
United States | UCSD | La Jolla | California |
United States | Rocky Mountain Cancer Centers | Lone Tree | Colorado |
United States | USC Norris Comprehensive Cancer Center | Los Angeles | California |
United States | The University Of Tennessee Health Science Center | Memphis | Tennessee |
United States | Sarah Cannon Research Institute | Nashville | Tennessee |
United States | SSM OKC Hightower Clinical | Oklahoma City | Oklahoma |
United States | Sarah Cannon Research Institute (Lake Nona) | Orlando | Florida |
United States | Oncology & Hematology Associates of Southwest Virginia | Roanoke | Virginia |
United States | SSM Health Saint Louis University Hospital | Saint Louis | Missouri |
United States | University of Utah Health Huntsman Cancer Hospital | Salt Lake City | Utah |
United States | Utah Cancer Specialists | Salt Lake City | Utah |
United States | Cancer Care Northwest | Spokane | Washington |
United States | Texas Oncology | Tyler | Texas |
Lead Sponsor | Collaborator |
---|---|
Merus N.V. |
United States, Belgium, France, Netherlands, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Escalation & Expansion: Biomarkers for Wnt signaling proteins | Evaluation of biomarker results for Wnt signaling proteins | 36 months | |
Other | Escalation & Expansion: Biomarkers for genetic aberrations in ctDNA | Evaluation of biomarker results in genetic aberrations in ctDNA | 36 months | |
Other | Escalation & Expansion: Biomarkers for differential expression of miRNA | Evaluation of biomarker results for differential expression of miRNA | 36 months | |
Other | Escalation & Expansion: Biomarkers for differential expression of mRNA | Evaluation of biomarker results for differential expression of mRNA | 36 months | |
Primary | Escalation: Number of patients with Dose Limiting Toxicities (DLTs) | Evaluation of number of participants with treatment related toxicities observed during the dose escalation. | 6-12 months | |
Primary | Escalation: Severity of Dose Limiting Toxicities (DLT) | Evaluation of the severity of treatment related toxicities observed during the dose escalation. | 6-12 months | |
Primary | Escalation and Expansion: Safety and tolerability: laboratory values | Number of participants with abnormal laboratory tests results | 6-12 months | |
Primary | Dose Expansion (Combination): Safety and tolerability: AEs and SAEs | Incidence, severity, and relationship of AEs and SAEs, in combination with pembrolizumab in HNSCC | 6-12 months | |
Primary | Escalation and Expansion: Safety and tolerability: (ECG) | Number of participants with abnormal ECG readings | 6-12 months | |
Primary | Escalation and Expansion: Safety and tolerability: vital signs | Number of participants with abnormal vital signs | 6-12 months | |
Primary | Escalation and Expansion: Safety and tolerability | Treatment discontinuations due to AEs and dose modifications due to AEs | 6-12 months | |
Primary | Expansion (single agent - non-randomized): Objective overall response rate (ORR) | Evaluation of clinical benefit assessed by RECIST v1.1 determining objective overall response rate (ORR) | 36 months | |
Primary | Escalation: RP2D | To determine the preliminary RP2D of single agent petosemtamab in mCRC patients who have progressed on chemotherapy, with or without an anti-vascular endothelial growth factor (VEGF) therapy, and with an anti-EGFR therapy (if RASwt) | 36 months | |
Primary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Incidence and severity and relationship of AEs and SAEs | To descriptively characterize all relevant clinical safety and efficacy data within the study | 12 months | |
Primary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Treatment discontinuations due to AEs and dose modifications due to AEs | To descriptively characterize all relevant clinical safety and efficacy data within the study | 12 months | |
Primary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Best overall response | To descriptively characterize all relevant clinical safety and efficacy data within the study | 12 months | |
Primary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Incidence of AEs and SAEs | To characterize the exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg Q2W in terms of TEAEs | 12 months | |
Primary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Incidence of TEAEs | To characterize the incidence of TEAEs at Week 8 | 8 weeks | |
Secondary | Escalation & Expansion: Incidence of anti-drug antibodies against MCLA-158 | Number of participants with anti-drug antibodies against MCLA-158 | 36 months | |
Secondary | Escalation & Expansion: Serum titers of anti-drug antibodies | Serum titers of anti-drug antibodies against MCLA-158 | 36 months | |
Secondary | Escalation & Expansion (non-randomized cohort): Cytokine Panel Expression Profile | Evaluation of the cytokine expression profile | 36 months | |
Secondary | Escalation & Expansion: Biomarkers for EGFR activation and signaling | Evaluation of biomarker results for EGFR activation and signaling | 36 months | |
Secondary | Escalation & Expansion: EGFR expression | Biomarkers in tumor samples relevant to EGFR expression in relation to early tumor response profile of MCLA-158 | 36 months | |
Secondary | Escalation & Expansion: LGR5 expression | Biomarkers in tumor samples relevant to LGR5 expression in relation to early tumor response profile of MCLA-158 | 36 months | |
Secondary | Escalation & Expansion: Duration of response (DOR) | Evaluation of clinical benefit assessed by RECIST v1.1 determining duration of response (DOR) | 36 months | |
Secondary | Escalation & Expansion: Progression Free Survival (PFS) and survival | Evaluation of clinical benefit assessed by RECIST v1.1 determining objective progression free survival (PFS) and/or survival | 36 months | |
Secondary | Escalation & Expansion: End of infusion (EOI) plasma concentration [Ceoi] | End of infusion (EOI) plasma concentration [Ceoi] as measured from all individual plasma concentrations | 36 months | |
Secondary | Escalation & Expansion: Maximum plasma concentration [Cmax] | Maximum plasma concentration as measured from all individual plasma concentrations | 36 months | |
Secondary | Escalation & Expansion: Plasma concentration at 0 hours [C0h] | Plasma concentration at 0 hours [C0h] as measured from all individual plasma concentrations | 36 months | |
Secondary | Escalation & Expansion: Area under the concentration versus time curve from time zero to time t [AUC0-t] | Area under the concentration versus time curve from time zero to time t [AUC0-t] | 36 months | |
Secondary | Escalation & Expansion: Area under the concentration versus time curve [AUC0-8] | Area under the concentration versus time curve [AUC0-8] | 36 months | |
Secondary | Escalation & Expansion: Clearance of plasma [CL] | Clearance of plasma [CL] | 36 months | |
Secondary | Escalation & Expansion: Volume of distribution at steady state [Vss] | Volume of distribution at steady state [Vss] | 36 months | |
Secondary | Escalation & Expansion: Time to reach maximum concentration [tmax] | Time to reach maximum concentration [tmax] | 36 months | |
Secondary | Escalation & Expansion: Half-life [t1/2] | Half-life [t1/2] | 36 months | |
Secondary | Expansion: Frequency of Treatment-Related Adverse Events (AE) | Evaluation of the number of participants with AEs or SAEs that are related to treatment as assessed by CTCAE version 4.03 | up to 30 days post-last dose | |
Secondary | Expansion: Severity of Treatment-Related Adverse Events (AE) | Evaluation of the severity of AEs that are related to treatment as assessed by CTCAE version 4.03 | up to 30 days post-last dose | |
Secondary | Expansion: Frequency of dose interruptions and reductions | Evaluation of the number of dose interruptions and reductions | up to 30 days post-last dose | |
Secondary | Escalation & Expansion: Overall survival (OS) | Evaluation of clinical benefit assessed by RECIST v1.1 determining overall survival (OS) | 36 months | |
Secondary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: Target Lesions | Percentage change from baseline in sum of the diameters of target lesions at Week 8 | 8 weeks | |
Secondary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: TEAEs | Incidence of Grade 3-4 TEAEs at Week 8 | 8 weeks | |
Secondary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: IRR TEAEs | Incidence of IRR TEAEs at Week 8 | 8 weeks | |
Secondary | Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg : non-IRR TEAEs | Incidence of non-IRR TEAEs at Week 8 | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |